Compare HRL & RNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HRL | RNA |
|---|---|---|
| Founded | 1891 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Meat/Poultry/Fish | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.5B | 227.6M |
| IPO Year | 1994 | 2025 |
| Metric | HRL | RNA |
|---|---|---|
| Price | $22.77 | $14.62 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 20 |
| Target Price | $27.33 | ★ $69.26 |
| AVG Volume (30 Days) | ★ 4.3M | 2.5M |
| Earning Date | 05-25-2026 | 01-01-0001 |
| Dividend Yield | ★ 5.08% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.33 | N/A |
| Revenue | ★ $12,106,160,000.00 | N/A |
| Revenue This Year | $2.82 | $88.12 |
| Revenue Next Year | $1.90 | $18.11 |
| P/E Ratio | $69.77 | ★ N/A |
| Revenue Growth | ★ 1.55 | N/A |
| 52 Week Low | $21.03 | $13.06 |
| 52 Week High | $32.07 | $73.06 |
| Indicator | HRL | RNA |
|---|---|---|
| Relative Strength Index (RSI) | 35.42 | 5.77 |
| Support Level | $22.24 | $13.06 |
| Resistance Level | $24.92 | $72.52 |
| Average True Range (ATR) | 0.63 | 0.94 |
| MACD | -0.25 | -2.87 |
| Stochastic Oscillator | 0.14 | 2.63 |
Historically meat-focused, Hormel Foods broadened its lineup to include other protein offerings and became a branded food company. The firm sells its wares through multiple channels, including US retail (61.6% of fiscal 2025 sales), US foodservice (32.6%), and international (5.9%). By product, 73% of fiscal 2025 sales were from perishable food and 27% from shelf-stable. Major brands include Hormel, Spam, Jennie-O, Columbus, Applegate, Planters, and Skippy. Many of these hold the number one or two market share in their respective categories.
Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.